AXL and neoplasm: It has exhibited reductions in tumor size in preclinical studies involving medullary thyroid and prostate cancers.[240, 241] Presently, a phase II clinical trial (NCT01639508) is ongoing in advanced NSCLC patients with various gene fusions or increased MET or AXL activity.